 This is a non-randomised, open labelled phase II trial in patients with relapsed or refractory multiple myeloma. Patients will be treated with: Bortezomib 1.3mgm2 bolus IV injection days 1, 4, 8 11 Dexamethasone 40mg po on days 1, 2, 3, 4 Doxorubicin 9mgm2day IV continuous infusion over days 1 - 4. In addition, for the first cycle only, Dexamethasone will also be given at 40mg po on days 8 - 11 and 15 - 18. 